Altitude Crest Partners’s BridgeBio Pharma BBIO Stock Holding History

Altitude Crest Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-612,060	Closed	-$18.9M	–	6
2024 Q1	$18.9M	Sell	612,060 -142,500	-19%	-$4.85M	8.1%	3
2023 Q4	$30.5M	Buy	+754,560	New	+$22.7M	20.38%	2

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altitude Crest Partners's BBIO Position: Q2 2024 in Review

Altitude Crest Partners sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 612,060 shares — an estimated $18.9M sold.

Altitude Crest Partners first reported a position in BBIO in Q4 2023 and held it in 2 quarters. The position peaked at $30.5M in Q4 2023. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

Altitude Crest Partners reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
Altitude Crest Partners sold 612,060 BridgeBio Pharma shares in Q2 2024, an estimated $18.9M.
Altitude Crest Partners first reported a position in BridgeBio Pharma in Q4 2023 and held it in 2 quarters.
Altitude Crest Partners's BridgeBio Pharma position peaked at $30.5M in Q4 2023.
251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.